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© 2010 The Japan Society of Histochemistry and Cy- Functional chemokine receptors are expressed in many malignant tumors. These receptors
promote tumor growth and metastasis in response to endogenous chemokines. We
analyzed the expression of CXCR4, CCR6 and CCR7 in fibrohistiocytic tumors, including
dermatofibrosarcoma protuberance (DFSP), malignant fibrous histiocytoma (MFH), dermato-
fibroma (DF) using immunohistochemistry. We also investigated the relationship between
CXCR4 and CD34, the latter of which is an immunohistochemical marker for DFSP. We ob-
served a higher expression of CXCR4 in DFSP and MFH as compared with DF. Interesting-
ly, a significantly higher expression of CXCR4 was detected in relapsed DFSP than in non-
relapsed DFSP, but no significant differences were detected between non-relapsed DFSP
and DFSP with CD34 immunostaining. Moreover, MFH had strong immunoreactivity for
CXCR4, CCR6 and CCR7. These findings suggest that the assessment of CXCR4 immuno-
reactivity in fibrohistiocytic tumors is a useful tool for predicting tumor aggressiveness.
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I. Introduction
Recently, functional chemokine receptors have been
shown to be expressed by a large number of human malig-
nancies, leading to the hypothesis that these chemokines
may stimulate the proliferation, chemotaxis, and site-
directed metastasis of tumor cells [14].
Chemokines are molecules that are structurally and
functionally similar to growth factors. They bind to G-
protein-coupled receptors on leukocytes and stem cells;
these receptors are termed this way because they work
through guanine-nucleotide-binding (G) proteins to initiate
the intracellular signaling cascades which prompt migra-
tion towards the chemokine source [4].
High CXCR4 expression was associated with metasta-
sis in breast cancer, malignant melanoma and papillary thy-
roid carcinoma [4, 8, 12]. Furthermore, recent studies have
shown that CXCR4 and CCR7 are consistently expressed in
breast cancer cells [4]. Interestingly, these matched chemo-
kines are known to be expressed in sites frequently involved
with breast cancer metastasis [4]. However, the role of
chemokines in the development of fibrohistiocytic tumors
has yet to be clarified.
Dermatofibrosarcoma protuberans (DFSP) is a highly
recurrent infiltrative skin tumor of intermediate malignancy.
The histogenesis of DFSP is still controversial. DFSP rarely
metastasizes (fewer than 10% of cases); however, extensive
resection is necessary because of its high tendency to recur.
On the other hand, malignant fibrohistiocytoma (MFH) is
the most frequently occurring soft-tissue sarcoma. MFH is
highly malignant, and the prognosis is very poor [2].
In this study, we investigated the immunohistochemi-
cal expression of CXCR4, CCR6 and CCR7 in paraffin-
embedded DFSP, MFH and dermatofibroma (DF) tissues
to assess the usefulness of assaying the altered expression
of these chemokine receptors for diagnosis and prognosis.
We also immunohistochemically investigated the relation-
ship between CXCR4 and CD34 which is an immuno-
histochemical marker for DFSP [3].Toyozawa et al. 46
II. Materials and Methods
Tissue samples
This study was performed on tumor tissues from 28
patients with fibrohistiocytic tumors, including 8 DFSP, 6
MFH, and 14 DF patients. These tissues were obtained from
the first surgery. The tissue specimens were fixed in neutral
buffered formalin, and then paraffin-embedded sections
were stained with hematoxylin-eosin (HE) [10]. All tumors
were histopathologically diagnosed by at least 3 dermatolo-
gists.
This study was approved by the ethics committee of the
Wakayama Medical University and informed consent was
obtained from each of the patients.
Immunohistochemistry
Immunohistochemistry was performed on deparaf-
finized, 4 µm-thick sections. The tissue sections were incu-
bated for 20 min in 3% H2O2 at room temperature (RT) to
block endogenous peroxidase activity, and then incubated in
a blocking solution (1% normal rabbit serum and 1% BSA)
to eliminate non-specific binding. The specimens were then
incubated for 2 hr at RT with a polyclonal goat anti-CXCR4
antibody (1:500 dilution; GeneTex, Inc., San Antonio, TX,
USA), anti-CCR6 antibody (1:300 dilution; GeneTex) or
anti-CCR7 antibody (1:300 dilution; GeneTex). Thereafter,
the specimens were incubated for 1 hr at RT with a biotiny-
lated secondary antibody (1:400 dilution; DAKO, Japan).
After extensive rinsing, they were developed using the
streptavidin-biotin-peroxidase complex technique (LSAB2
kit/HRP, DAKO).
CD34 immunostaining was performed with an anti-
CD34 antibody (1:200 dilution; DAKO). The sections were
incubated for 2 hr at RT with this antibody. The bound
primary antibodies were then detected using an Envision
labeled polymer (DAKO). The peroxidase reaction was
visualized with 0.2 mg/ml 3,3'-diaminobenzidine tetra-
hydrochloride. The sections were counter-stained with
hematoxylin. The control sections were not exposed to the
primary antibody.
Evaluation of immunolabeling
The immunohistochemical scoring was performed in-
dependently by 3 dermatologists or a pathologist who had no
clinical knowledge of the patients and who were blinded to
the procedure. The immunostained sections were scanned by
light-microscopy. Necrotic areas and the edges of the tissue
sections were not included in the counting. The immuno-
histochemical staining was scored on a 0 to 4 scale on one
field as follows: 0 (membranous or cytoplasmic labeling
either absent or less than 5% of the tumor cells), 1 (in 5–
50% of the tumor cells), 2 (in 50–70% of the tumor cells),
3 (in 70–90% of the tumor cells), or 4 (in 90–100% of the
tumor cells). In each specimen, 5 fields of ×400 high power
view were assessed randomly in all specimens. The im-
munostaining score of each specimen is presented by total
scores in all 5 fields. We marked on a maximum scale of
20 points (=0~4 ranks×5 fields).
Statistical analysis
Statistical significance was evaluated using a one-way
analysis of variance with posthoc testing with Scheffe’s F
multiple comparison tests. P<0.05 was regarded as statisti-
cally significant.
III. Results
Tumor characteristics and patient profiles
The characteristics of the patients are shown in Table 1.
Three of the 8 DFSP patients relapsed within 3 years after
the first operation, but none of the DFSP cases had lymph
node metastasis or distant metastasis. Two of the 6 MFH
patients relapsed within 3 years, and only 1 case of MFH
had a lung metastasis within 2 years after the first operation.
High expression of CXCR4 in relapsed DFSP and MFH
Representative results of the immunohistochemical
staining for CXCR4 are shown in Figure 1. CXCR4 immu-
noexpression was detected in 8/8 (100%) cases of DFSP,
6/6 cases (100%) of MFH, 12/14 (86%) cases of DF.
As shown in Figure 2, the average scores of the CXCR4
Table 1. Patients and tumor characteristics
NOTE. The numbers in parentheses are percentages.
DFSP MFH DF
Total number of patients 8 6 14
Median age 47.9 61.5 31.1
Gender Female 6 (75) 2 (33) 11 (79)
Male 2 (25) 4 (67) 3 (21)
Tumor size <2 cm 0 (0) 1 (17) 14 (100)
2~5 cm 2 (25) 4 (67) 0 (0)
>5 cm 6 (75) 1 (17) 0 (0)
Relapse or metastasis within 3 years Yes 3 (38) 3 (50)
(one of 3; lung metastasis)
0 (0)
No 5 (62) 0 (0) 14 (100)
Resected within 3 years 0 (0) 3 (50) 0 (0)CXCR4 Expression in Fibrohistiocytic Tumors 47
immunostaining were significantly higher in DFSP and
MFH as compared with DF (p<0.01). Moreover, CXCR4
immunoexpression was significantly higher in relapsed
DFSP as compared with non-relapsed DFSP (p<0.01).
However, there was no difference in immunostaining
intensity between the two DFSP groups.
High expression of CCR6 and CCR7 in MFH
The immunohistochemical staining results for CCR6
are shown in Figure 3. As shown in Figure 4, the average
scores for the CCR6 immunostaining were significantly
higher in only MFH as compared with DF (p<0.01).
However, no significant difference in immunostaining score
was observed between non-relapsed DFSP and relapsed
DFSP.
The immunohistochemical staining results for CCR7
are shown in Figure 5. As shown in Figure 6, the average
scores for CCR7 immunostaining were significantly higher
in non-relapsed DFSP (p<0.05) and MFH (p<0.01) as
compared with DF. However, no significant difference in
immunostaining score was observed between non-relapsed
DFSP and relapsed DFSP.
Fig. 1. CXCR4 immunoexpression in fibrohistiocytic tumors (×200). A. No expression of CXCR4 was observed in non-relapsed DFSP. B. Dif-
fuse CXCR4 expression was observed in relapsed DFSP. C. Diffuse CXCR4 expression was observed in MFH. D. No expression of CXCR4
was observed in DF.
Fig. 2. The mean score of CXCR4-positive tumor cells. The mean
scores of the CXCR4 immunostaining were significantly higher in
DFSP and MFH as compared with DF (p<0.01). Moreover, CXCR4
immunoexpression was significantly higher in relapsed DFSP as com-
pared with non-relapsed DFSP (p<0.01).
Statistics
Non-relapsed DFSP
vs relapsed DFSP p<0.01; vs MFH p<0.01; vs DF p<0.05
Relapsed DFSP
vs MFH p<0.01; vs DF p<0.01
MFH
vs DF p<0.01Toyozawa et al. 48
Expression of CD34 in DFSP
Anti-CD34 reacted in most of the tumor cells in 2/8
(25%) cases of DFSP, and there was partial immunoreac-
tivity in 5/8 (63%) cases, and no immunoreactivity in 1/8
(13%) case.
In the 3 relapsed DFSP cases, anti-CD34 immuno-
reactivity was detected in 2 cases (Fig. 7A), but not in 1
case (Fig. 7B).
As shown in Figure 8, no significant difference in the
average scores for CD34 immunostaining was observed
between non-relapsed DFSP and relapsed DFSP.
IV. Discussion
Recent studies have demonstrated the ability of
chemokines to induce cell migration during cancer metasta-
sis [14]. CXCR4 is the physiological receptor for CXCL12,
which belongs to a chemokine family that has potent chemo-
tactic activity for lymphocytes. Studies have determined that
an upregulation of CXCR4 is observed in breast cancer,
squamous cell carcinoma of the head and neck, colorectal
cancer, thyroid carcinoma and malignant melanoma [4–6, 9,
13]. However, this chemokine receptor expression pattern
has not been previously analyzed in fibrohistiocytic tumors.
In this study, immunohistochemical analyses revealed that
CXCR4 immunoreactivity was thought to be related to
tumor aggressiveness in fibrohistiocytic tumors.
CXCR4, CCR6 and CC7 have a potential to be immuno-
histochemical indicators of tumor aggressiveness of MFH
MFH is a sarcoma of either fibroblastic or primitive
mesenchymal origin, which manifests features of both fibro-
blastic and histiocytic differentiation. MFH tends to metas-
tasize distantly. In our study, significantly high immuno-
reactivity for CXCR4, CCR6, and CCR7 was detected in
6/6 cases of MFH, which have the tendency to metastasize.
Recent studies have shown that CXCR4 and CCR7
are consistently expressed in breast cancer cells [4]. Con-
Fig. 3. CCR6 immunoexpression in fibrohistiocytic tumors (×200). A. Diffuse CCR6 expression was observed in non-relapsed DFSP. B. Dif-
fuse CCR6 expression was observed in relapsed DFSP. C. Diffuse CCR6 expression was observed in MFH. D. No expression of CCR6 was
observed in DF.
Fig. 4. The mean score of CCR6-positive tumor cells. The mean
score of the CCR6 immunostaining was significantly higher in only
MFH as compared with DF (p<0.01).CXCR4 Expression in Fibrohistiocytic Tumors 49
sidering that these matched chemokines are known to be
expressed in sites frequently involved with breast cancer
metastasis, it is possible that an assessment of the expres-
sion of these chemokines in MFH may be a useful tool for
predicting tumor aggressiveness.
The assessment of CXCR4 immunoreactivity is a useful tool 
for predicting tumor aggressiveness of DFSP
DFSP is highly invasive locally, but rarely metasta-
sizes, even after recurrence. It is often difficult to determine
the optimal therapy, including the range of excision. In
1990, the first report appeared demonstrating that cells from
DFSP express the human progenitor antigen CD34 on
their surface [3]. Aiba et al. reported that they found strongly
positive staining of tumor cells for the CD34 antigen in all
seven cases of DFSP [1]. Most studies have documented the
prevalence of CD34 staining in DFSP as ranging from 84%
to 100% [11].
On the other hand, several reports suggest that the
sarcomatous changes in DFSP, which represents a form
of tumor progression, showed weak CD34 immunoreac-
tivity [7]. To date, however, definite markers predicting the
aggressiveness and recurrence potential of DFSP have
not been established. In our study, 7/8 (87.5%) cases of
DFSP had CD34 immunoreactivity. However, there was no
significant difference in CD34 immunoreactivity between
non-relapsed DFSP and relapsed DFSP. Therefore, it seems
difficult to regard CD34 as a prognostic indicator of DFSP.
In contrast, our study showed CXCR4 immunoreac-
tivity was significantly higher (i.e. the number of CXCR4
immunopositive cells) in relapsed DFSP as compared with
non-relapsed DFSP. There was no significant difference in
the immunoexpression of CCR6 or CCR7.
Our present study revealed that: (i) MFH had a strong
expression of CXCR4, CCR6, and CCR7 immunoreactivity
as compared with DF. These data suggest that an assessment
of the expression of these chemokines in MFH may be a use-
ful tool for predicting tumor aggressiveness. (ii) CXCR4
Fig. 5. CCR7 immunoexpression in fibrohistiocytic tumors (×200). A. Diffuse CCR7 expression was observed in non-relapsed DFSP. B. Dif-
fuse CCR7 expression was observed in relapsed DFSP. C. Diffuse CCR7 expression was observed in MFH. D. No expression of CCR7 was
observed in DF.
Fig. 6. The mean score of CCR7-positive tumor cells. The mean
score of CCR7 immunostaining was significantly higher in non-
relapsed DFSP (p<0.05) and MFH (p<0.01) as compared with DF.Toyozawa et al. 50
immunoreactivity was significantly higher in relapsed DFSP
than in non-relapsed DFSP, even though CD34 immuno-
reactivity showed no significant differences between the
two DFSP groups. These data suggest that the assessment of
CXCR4 immunoreactivity in DFSP is a useful tool for pre-
dicting tumor aggressiveness.
To confirm these data, additional research with larger
study populations will be necessary.
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Fig. 7. CD34 immunoexpression in relapsed DFSP (×200). A. CD34 positive case of relapsed DFSP. B. CD34 negative case of relapsed DFSP.
Fig. 8. The mean score of CD34-positive tumor cells. No significant
difference in the mean score of CD34 immunostaining was
observed between non-relapsed DFSP and relapsed DFSP.